CD8A and neoplasm: After the use of combination immunotherapy, an increase in T helper type 1 cytokines, ICOS+Ki67+CD4+, and ICOS+Ki67+CD8+ T-cells was observed as well as an increased CD8+ Tcell/FoxP3+ Treg ratio within the tumor.